Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

April 6, 2018: By Jon Swedien

Alcon, Allergan, and Bausch + Lomb are among the companies that have petitioned the US Supreme Court to hear a case challenging the size of eye drops.

The petition comes in the wake of conflicting federal appeals court decisions in similar cases brought by patients who use glaucoma medications. Plaintiffs in both cases argued that the drugmakers should sell bottles that dispense smaller drops, which would waste less product and save consumers money.

One of the appeals court decisions (Cottrell v. Alcon) sided with plaintiff. In the other case (Eike v. Allergan)—with similar allegations—the court found in favor of the companies. The companies petitioned the high court to hear Cottrell v. Alcon.

In Cottrell v. Alcon, the plaintiffs pointed to studies sponsored and published by the defendants that found eye drops should be 5 to 15 μLs in order to maximize the amount of the medication entering the inner eye. The plaintiffs went on to note that the size of the defendants’ eye drops was more than two- to three times the maximum recommended size in the studies, and as such, led to wasted product.

In their petition, the companies defended their products’ packaging, noting it is FDA approved. They also argued that smaller drops, for numerous reasons, would not necessarily result in lower prices—and that the cost of changing the drop size could actually be passed onto consumers.

“Whether petitioners would be able to offer smaller drops (and, if so, at what price) is itself significantly affected by FDA and its approval process and post-approval requirements,” the petition said.

The Supreme Court hears just a small fraction of the cases it is asked to take up each year, but it does tend to favor cases where circuit courts have made conflicting rulings.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT